Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -45.47% | 17.70% | -23.92% | -77.21% | -86.55% |
| Total Depreciation and Amortization | 5.08% | 12.26% | 48.15% | 29.67% | 29.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.46% | -1.96% | 210.83% | 1,090.80% | 1,245.59% |
| Change in Net Operating Assets | 126.39% | -106.40% | 192.74% | 696.23% | -738.89% |
| Cash from Operations | 39.86% | -44.26% | 50.98% | 26.93% | -149.41% |
| Capital Expenditure | -- | -150.00% | 8.33% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -150.00% | 8.33% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.44% | -98.34% | 484.69% | -- | -93.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 99.96% | -313,150.00% | -- | 97.57% |
| Cash from Financing | -91.22% | -98.21% | 449.69% | -- | -93.15% |
| Foreign Exchange rate Adjustments | 90.00% | -219.05% | -146.32% | 190.53% | -2,300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.31% | -116.05% | 803.36% | -119.23% | -115.20% |